We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00868426
Recruitment Status : Completed
First Posted : March 25, 2009
Last Update Posted : August 13, 2009
Sponsor:
Information provided by:

Study Description
Brief Summary:
The aim of this pilot study is to assess the methodology, practical arrangements and pulmonary absorption with charcoal blockage for the future bioequivalence studies. In addition, PK of budesonide and formoterol after administration from 2 different batches of Symbicort TH is compared with each other.

Condition or disease Intervention/treatment Phase
Healthy Drug: Budesonide/Formoterol Batch 1 Drug: Budesonide/Formoterol Batch 2 Drug: Budesonide/Formoterol Batch 1 and charcoal Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler, Symbicort Turbuhaler; an Open, Single Center, Single Dose Study With 3-way Crossover Design in Healthy Subjects
Study Start Date : April 2009
Primary Completion Date : May 2009
Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
Budesonide/Formoterol Batch 1
Drug: Budesonide/Formoterol Batch 1
Single, inhaled dose
Other Name: Symbicort Turbuhaler
Experimental: 2
Budesonide/Formoterol Batch 2
Drug: Budesonide/Formoterol Batch 2
Single, inhaled dose
Other Name: Symbicort Turbuhaler
Experimental: 3
Budesonide/Formoterol Batch 1 and charcoal
Drug: Budesonide/Formoterol Batch 1 and charcoal
Single, inhaled dose
Other Name: Symbicort Turbuhaler


Outcome Measures

Primary Outcome Measures :
  1. Assess the methodology, practical arrangements and pulmonary absorption with charcoal blockage [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Pharmacokinetics of budesonide and formoterol after administration of two different batches of Symbicort Turbuhaler [ Time Frame: 1 day ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Good general health ascertained by detailed medical history, and laboratory and physical examinations
  • Finnish speaking males and females, 18-55 (inclusive) years of age
  • Normal weight defined as body mass index (BMI) > 19 and < 30 kg/m2
  • Weight at least 50 kg
  • Regular intestinal transit

Exclusion Criteria:

  • Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease
  • Any abnormal value of laboratory, vital signs, 12-lead electrocardiogram or physical exam which may in the opinion of the investigator interfere with the test results or cause a health risk for the subject if he/she takes part into the study
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study
  • Known hypersensitivity to the active substance(s) or to any of the excipients of the drug
  • Pregnant or lactating females
  • Recent or current (suspected) drug abuse or positive result in the drugs abuse test
  • Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 16 units per week for females [1 unit = 4 cl spirits or equivalent])
  • Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study
  • Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from the use of caffeine containing beverages during the treatment periods until 24 h after study treatment administration
  • Blood donation or loss of significant amount of blood within 90 days prior to the first study treatment administration
  • Administration of another investigational drug within 90 days prior to the first study treatment administration
  • Unsuitable veins for repeated venipuncture or for cannulation
  • Inability to learn the correct inhalation technique
  • Inability to participate in all treatment periods
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00868426


Locations
Finland
Orion Pharma Phase I Unit
Espoo, Finland, 02101
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Investigators
Principal Investigator: Kimmo Ingman, MD, PhD Orion Corporation, Orion Pharma
More Information

Responsible Party: Ulla Sairanen, Clinical study director, Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier: NCT00868426     History of Changes
Other Study ID Numbers: 3103001
First Posted: March 25, 2009    Key Record Dates
Last Update Posted: August 13, 2009
Last Verified: July 2009

Keywords provided by Orion Corporation, Orion Pharma:
Healthy volunteer study

Additional relevant MeSH terms:
Formoterol Fumarate
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Charcoal
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antidotes
Protective Agents